Baxter International Inc. $BAX Shares Purchased by Wedmont Private Capital

Wedmont Private Capital lifted its stake in shares of Baxter International Inc. (NYSE:BAX) by 74.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,891 shares of the medical instruments supplier’s stock after purchasing an additional 21,356 shares during the period. Wedmont Private Capital’s holdings in Baxter International were worth $1,129,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Baird Financial Group Inc. increased its holdings in shares of Baxter International by 3.2% during the 2nd quarter. Baird Financial Group Inc. now owns 52,436 shares of the medical instruments supplier’s stock valued at $1,588,000 after acquiring an additional 1,604 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Baxter International by 2.9% in the second quarter. California State Teachers Retirement System now owns 649,463 shares of the medical instruments supplier’s stock valued at $19,666,000 after buying an additional 18,439 shares during the period. Ameriprise Financial Inc. increased its position in shares of Baxter International by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock valued at $231,304,000 after purchasing an additional 97,687 shares during the period. BI Asset Management Fondsmaeglerselskab A S raised its stake in shares of Baxter International by 21.4% in the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 24,356 shares of the medical instruments supplier’s stock valued at $737,000 after buying an additional 4,293 shares in the last quarter. Finally, Captrust Financial Advisors lifted its stake in Baxter International by 5.5% during the second quarter. Captrust Financial Advisors now owns 53,933 shares of the medical instruments supplier’s stock worth $1,633,000 after purchasing an additional 2,813 shares during the period. 90.19% of the stock is owned by hedge funds and other institutional investors.

Baxter International Trading Down 3.7%

Shares of NYSE:BAX opened at $24.87 on Wednesday. Baxter International Inc. has a 52-week low of $15.73 and a 52-week high of $30.00. The company has a 50-day simple moving average of $24.87 and a 200 day simple moving average of $20.78. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.32 and a current ratio of 1.95. The company has a market capitalization of $12.86 billion, a P/E ratio of -12.01, a price-to-earnings-growth ratio of 3.91 and a beta of 0.60.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.59 earnings per share. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Sell-side analysts forecast that Baxter International Inc. will post 2.04 earnings per share for the current year.

Baxter International Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be paid a $0.01 dividend. The ex-dividend date is Friday, August 28th. This represents a $0.04 annualized dividend and a yield of 0.2%. Baxter International’s payout ratio is -1.93%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. TD Cowen lifted their price target on shares of Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a report on Monday, July 27th. UBS Group upped their target price on shares of Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a research report on Tuesday, July 28th. Stifel Nicolaus increased their target price on shares of Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a report on Tuesday, July 28th. Wall Street Zen upgraded Baxter International from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, The Goldman Sachs Group increased their target price on Baxter International from $19.00 to $21.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Baxter International has a consensus rating of “Hold” and an average target price of $22.45.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.